AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10817716 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemifloxacin 80 mg
Number of subjects: 0
Study 10817716 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemifloxacin 160 mg
Number of subjects: 0
Study 10817716 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemifloxacin 320 mg
Number of subjects: 0
Study 10817716 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemifloxacin 600 mg
Number of subjects: 0
Study 10817716 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemifloxacin 800 mg
Number of subjects: 0
Study 8647328 — intervention group
Group type: EXPERIMENTAL
Intervention: Semantic-pragmatic language disorder group
Number of subjects: 0
Study 8647328 — intervention group
Group type: EXPERIMENTAL
Intervention: High-level autism group
Number of subjects: 0
Study 8647328 — intervention group
Group type: COMPARATOR
Intervention: Control group of normal children
Number of subjects: 0
Study 2052460 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline
Number of subjects: 2
Study 2052460 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxapram
Number of subjects: 2
Study 2052460 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of aminophylline and doxapram
Number of subjects: 2
Study 7083219 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal (25 g orally at 12, 18, 24, 36, and 48 hours)
Number of subjects: 15
Study 7083219 — intervention group
Group type: COMPARATOR
Intervention: Control (no activated charcoal)
Number of subjects: 15
Study 31206787 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based NB-UVB phototherapy
Number of subjects: 100
Study 31206787 — intervention group
Group type: COMPARATOR
Intervention: Hospital-based NB-UVB phototherapy
Number of subjects: 100
Study 30519898 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estrogen
Number of subjects: 317
Study 30519898 — intervention group
Group type: COMPARATOR
Intervention: Oral estrogen
Number of subjects: 317
Study 28560383 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg genistein daily for 3-6 weeks
Number of subjects: 0
Study 28560383 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules daily for 3-6 weeks
Number of subjects: 0
Study 24994573 — intervention group
Group type: EXPERIMENTAL
Intervention: Postnatal psychoeducation programme
Number of subjects: 180
Study 24994573 — intervention group
Group type: COMPARATOR
Intervention: Routine postnatal care
Number of subjects: 180
Study 23432415 — intervention group
Group type: EXPERIMENTAL
Intervention: Netazepide 100 mg
Number of subjects: 0
Study 23432415 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg
Number of subjects: 0
Study 23432415 — intervention group
Group type: EXPERIMENTAL
Intervention: Netazepide (various doses 5, 10, 25 mg)
Number of subjects: 0
Study 23432415 — intervention group
Group type: EXPERIMENTAL
Intervention: Netazepide (various doses)
Number of subjects: 0
Study 23432415 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21491420 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV vaccine
Number of subjects: 865
Study 21491420 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 865
Study 19111850 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug and nutritional supplements trials
Number of subjects: 7941
Study 19111850 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of evidence from randomized controlled trials
Number of subjects: 7941
Study 17258381 — intervention group
Group type: EXPERIMENTAL
Intervention: TOT surgery performed by an experienced surgeon (Group 1, n=30)
Number of subjects: 60
Study 17258381 — intervention group
Group type: COMPARATOR
Intervention: TOT surgery performed by a senior resident under supervision (Group 2, n=30)
Number of subjects: 60
Study 14987305 — intervention group
Group type: EXPERIMENTAL
Intervention: Mequitazine 5 mg
Number of subjects: 18
Study 14987305 — intervention group
Group type: EXPERIMENTAL
Intervention: Mequitazine 10 mg
Number of subjects: 18
Study 14987305 — intervention group
Group type: EXPERIMENTAL
Intervention: Mequitazine 15 mg
Number of subjects: 18
Study 14987305 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexchlorpheniramine 6 mg
Number of subjects: 18
Study 14987305 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 18
Study 14987305 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 11276370 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (Cy) + Granulocyte Colony-Stimulating Factor (GCSF)
Number of subjects: 35
Study 11276370 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
Number of subjects: 35
Study 11276370 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF followed by GCSF
Number of subjects: 35
Study 11276370 — intervention group
Group type: COMPARATOR
Intervention: All arms (A, B, C)
Number of subjects: 35
Study 11276370 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor mobilizers (failed to mobilize 0.4 x 10(6) CD34(+) cells/kg in 2 days)
Number of subjects: 35
Study 11276370 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful mobilizers (mobilized 0.4 x 10(6) CD34(+) cells/kg in 2 days)
Number of subjects: 35
Study 9135927 — intervention group
Group type: EXPERIMENTAL
Intervention: Miglitol (50 mg t.i.d., followed by 100 mg t.i.d.)
Number of subjects: 201
Study 9135927 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide (3.5 mg q.d/b.i.d.)
Number of subjects: 201
Study 9135927 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study 7970848 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic co-trimoxazole
Number of subjects: 14
Study 7970848 — intervention group
Group type: EXPERIMENTAL
Intervention: Counts of > 20 bacteria adherent to bladder cells
Number of subjects: 14
Study 7970848 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroquinolone therapy
Number of subjects: 14
Study 7970848 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole
Number of subjects: 14
Study 7970848 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (0.1, 0.5, 1.0 micrograms/ml)
Number of subjects: 14
Study 7970848 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin
Number of subjects: 14
Study 7970848 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin
Number of subjects: 14
Study 3315645 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 weeks daily PMR instruction provided in class for academic credit (n = 51)
Number of subjects: 1400
Study 3315645 — intervention group
Group type: COMPARATOR
Intervention: Control condition (n = 59)
Number of subjects: 1400
Study 28787759 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG) fluorescence imaging (FI) at 0.25 mg per kg of patient weight injected intraoperatively after explorative laparotomy before CS.
Number of subjects: 20
Study 28787759 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG) fluorescence imaging (FI) for detecting tumor cells in post-NAC scars.
Number of subjects: 20
Study 28787759 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG) fluorescence imaging (FI) for detecting tumor cells in scars.
Number of subjects: 20
Study 27097736 — intervention group
Group type: EXPERIMENTAL
Intervention: High variety support exercise program
Number of subjects: 121
Study 27097736 — intervention group
Group type: COMPARATOR
Intervention: Low variety support exercise program
Number of subjects: 121
Study 24612164 — intervention group
Group type: EXPERIMENTAL
Intervention: e-learning condition
Number of subjects: 3784
Study 24612164 — intervention group
Group type: EXPERIMENTAL
Intervention: integral condition
Number of subjects: 3784
Study 22587483 — intervention group
Group type: COMPARATOR
Intervention: rosiglitazone (4-8 mg/day)
Number of subjects: 373
Study 22587483 — intervention group
Group type: COMPARATOR
Intervention: pioglitazone (15-45 mg/day)
Number of subjects: 373
Study 22587483 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 373
Study 19922492 — intervention group
Group type: EXPERIMENTAL
Intervention: Cylindrical implant (group A)
Number of subjects: 0
Study 19922492 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapered implant (group B)
Number of subjects: 0
Study 17448971 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron ferrous sulphate (256 mg/day; 80 mg of Fe(2+)), vitamin C (1000 mg/day), and folic acid (5mg/day) during the 30‐45 days preceding surgery (Group 2)
Number of subjects: 156
Study 17448971 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 1)
Number of subjects: 156
Study 15519131 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg LEV
Number of subjects: 10
Study 15519131 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 mg LEV
Number of subjects: 10
Study 15519131 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 12054147 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate (60 mg iv weekly for three consecutive doses, followed by one infusion every 3 weeks for a total of 24 infusions)
Number of subjects: 200
Study 12054147 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate
Number of subjects: 200
Study 9754184 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperopic PRK with the VISX STAR Excimer Laser System
Number of subjects: 38
Study 8160979 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced-air warming during surgery
Number of subjects: 127
Study 8160979 — intervention group
Group type: COMPARATOR
Intervention: Conventional warmed cotton blankets
Number of subjects: 127
Study 8160979 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced-air warming during and after surgery
Number of subjects: 127
Study 8160979 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative warming
Number of subjects: 127
Study 8160979 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced-air warming
Number of subjects: 127
Study 3258001 — intervention group
Group type: EXPERIMENTAL
Intervention: Solarium radiation (not filtered through Mylar sheeting) for 30 min on 12 consecutive days
Number of subjects: 10
Study 3258001 — intervention group
Group type: EXPERIMENTAL
Intervention: Solarium radiation (filtered through 0.1 mm thick Mylar sheeting) for 30 min on 12 consecutive days
Number of subjects: 10
Study 3258001 — intervention group
Group type: COMPARATOR
Intervention: Untreated group (no exposure to solarium radiation)
Number of subjects: 10
Study 28434415 — intervention group
Group type: EXPERIMENTAL
Intervention: Incredible Years (IY) behavioral parent training program
Number of subjects: 387
Study 28434415 — intervention group
Group type: EXPERIMENTAL
Intervention: Incredible Years (IY)
Number of subjects: 387
Study 27546308 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Fe formula (6.6 mg Fe/d)
Number of subjects: 72
Study 27546308 — intervention group
Group type: COMPARATOR
Intervention: Low-Fe formula (1.3 mg Fe/d)
Number of subjects: 72
Study 27546308 — intervention group
Group type: EXPERIMENTAL
Intervention: Fe drops (6.6 mg Fe/d)
Number of subjects: 72
Study 24709874 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific resistance training for the neck/shoulder muscles three times a week
Number of subjects: 131
Study 24709874 — intervention group
Group type: COMPARATOR
Intervention: Advice to stay active (Control group)
Number of subjects: 131
Study 23582414 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 454
Study 23582414 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy (MED)
Number of subjects: 454
Study 20836606 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluative conditioning using positive social stimuli (pictures of smiling faces) linked to pictures of their own bodies
Number of subjects: 54
Study 20836606 — intervention group
Group type: COMPARATOR
Intervention: Control condition with random association of pictures of their own body and control bodies with positive, neutral, and negative social stimuli
Number of subjects: 54
Study 19127917 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal needle combined with Tuina therapy
Number of subjects: 150
Study 16368842 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric 0.5% bupivacaine at 37 degrees C
Number of subjects: 36
Study 16368842 — intervention group
Group type: COMPARATOR
Intervention: Hyperbaric 0.5% bupivacaine at 25 degrees C
Number of subjects: 36
Study 15014407 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (aspirin)
Number of subjects: 36
Study 15014407 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib (Vioxx)
Number of subjects: 36
Study 15014407 — intervention group
Group type: COMPARATOR
Intervention: Control group (no drug)
Number of subjects: 36
Study 11704116 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 IU of recombinant FSH
Number of subjects: 404
Study 11704116 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 IU of recombinant FSH
Number of subjects: 404
Study 9632034 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily venlafaxine (37.5 mg daily, increased up to 225 mg daily)
Number of subjects: 48
Study 9632034 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily venlafaxine (37.5 mg daily, increased up to 225 mg daily)
Number of subjects: 48
Study 9632034 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 48
Study 7890902 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha-2a therapy
Number of subjects: 14
Study 3223118 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (additional to ampicilline and metronidazol for 10 days)
Number of subjects: 59
Study 3223118 — intervention group
Group type: COMPARATOR
Intervention: Ampicilline and metronidazol (without prednisolone)
Number of subjects: 59
Study 28401595 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive music training (12 bi-weekly 70-min sessions)
Number of subjects: 35
Study 28401595 — intervention group
Group type: COMPARATOR
Intervention: Control group (12 bi-weekly 45-min sessions of gymnastic activities)
Number of subjects: 35
Study 28493347 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loading
Number of subjects: 39
Study 28493347 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed loading
Number of subjects: 39
Study 28493347 — intervention group
Group type: EXPERIMENTAL
Intervention: Early loading
Number of subjects: 39
Study 23666533 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser (Ul, N=20 and Ll, N=20)
Number of subjects: 120
Study 23666533 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Up, N=20 and Lp, N=20)
Number of subjects: 120
Study 23666533 — intervention group
Group type: COMPARATOR
Intervention: Control (Uc, N=20 and Lc, N=20)
Number of subjects: 120
Study 22795720 — intervention group
Group type: EXPERIMENTAL
Intervention: Early eptifibatide
Number of subjects: 9406
Study 22795720 — intervention group
Group type: COMPARATOR
Intervention: Delayed provisional eptifibatide
Number of subjects: 9406
Study 21616512 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose insulin therapy (5 mU·kg(‐1)·min(‐1) starting at skin incision)
Number of subjects: 20
Study 21616512 — intervention group
Group type: COMPARATOR
Intervention: Standard metabolic care (target glycemia 6.0‐10.0 mmol/L, n = 10)
Number of subjects: 20
Study 21616512 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose insulin therapy
Number of subjects: 20
Study 18431002 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (EG) received four-day-in-a-row treatment with 10 degrees rightward deviating prisms.
Number of subjects: 16
Study 18431002 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) received four-day-in-a-row placebo treatment.
Number of subjects: 16
Study 18431002 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (EG) at one month post-treatment.
Number of subjects: 16
Study 18431002 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) at one month post-treatment.
Number of subjects: 16
Study 16918222 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BTA) injections in ankle flexors, hamstrings, and adductors
Number of subjects: 0
Study 16918222 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BTA) injections
Number of subjects: 0
Study 12787037 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% fluocinolone acetonide in orabase (FAO)
Number of subjects: 97
Study 12787037 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% fluocinolone acetonide solution (FAS)
Number of subjects: 97
Study 12787037 — intervention group
Group type: EXPERIMENTAL
Intervention: Both 0.1% fluocinolone acetonide solution and in orabase (FAS/FAO)
Number of subjects: 97
Study 12787037 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 97
Study 10735680 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (200,000 KIU bolus + 100,000 KIU/h for 8 hours)
Number of subjects: 171
Study 10735680 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study 9186336 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral resection of the prostate
Number of subjects: 52
Study 9186336 — intervention group
Group type: COMPARATOR
Intervention: High energy microwave thermotherapy
Number of subjects: 52
Study 1550278 — intervention group
Group type: EXPERIMENTAL
Intervention: Transaortic plexus block
Number of subjects: 61
Study 1550278 — intervention group
Group type: EXPERIMENTAL
Intervention: Classic retrocrural block
Number of subjects: 61
Study 1550278 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral chemical splanchnicectomy
Number of subjects: 61
Study 3924533 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (650 mg qid) with Misoprostol (25 micrograms qid)
Number of subjects: 32
Study 3924533 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (650 mg qid) with Placebo
Number of subjects: 32
Study 31719075 — intervention group
Group type: EXPERIMENTAL
Intervention: Timed Up-and-Go (TUG)
Number of subjects: 128
Study 31719075 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated Chair Stands (RCS)
Number of subjects: 128
Study 31719075 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking Speed Tests
Number of subjects: 128
Study 27797014 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-framed (GF) message
Number of subjects: 732
Study 27797014 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss-framed (LF) message
Number of subjects: 732
Study 27797014 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-regulatory efficacy-enhancing (SRE) message
Number of subjects: 732
Study 27797014 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-framed plus SRE (GF + SRE) message
Number of subjects: 732
Study 27797014 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss-framed plus SRE (LF + SRE) message
Number of subjects: 732
Study 27797014 — intervention group
Group type: EXPERIMENTAL
Intervention: All conditions
Number of subjects: 732
Study 25478993 — intervention group
Group type: EXPERIMENTAL
Intervention: MOO group
Number of subjects: 1302
Study 25478993 — intervention group
Group type: EXPERIMENTAL
Intervention: MHO group
Number of subjects: 1302
Study 25478993 — intervention group
Group type: EXPERIMENTAL
Intervention: MONO group
Number of subjects: 1302
Study 25478993 — intervention group
Group type: EXPERIMENTAL
Intervention: MHNO group
Number of subjects: 1302
Study 25478993 — intervention group
Group type: COMPARATOR
Intervention: All groups (MHNO to MOO)
Number of subjects: 1302
Study 25478993 — intervention group
Group type: EXPERIMENTAL
Intervention: Adiponectin
Number of subjects: 1302
Study 25478993 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF‐α
Number of subjects: 1302
Study 25478993 — intervention group
Group type: EXPERIMENTAL
Intervention: hs‐CRP
Number of subjects: 1302
Study 25478993 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxidized LDL
Number of subjects: 1302
Study 24112149 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium bromide (5 µg) via Respimat
Number of subjects: 338
Study 24112149 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 338
Study 21821304 — intervention group
Group type: EXPERIMENTAL
Intervention: 16Gy boost dose
Number of subjects: 1603
Study 21821304 — intervention group
Group type: COMPARATOR
Intervention: No boost
Number of subjects: 1603
Study 21821304 — intervention group
Group type: EXPERIMENTAL
Intervention: High grade invasive tumors
Number of subjects: 1603
Study 21821304 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram including histologic grade, DCIS, tumor diameter, age, tamoxifen, chemotherapy, and boost
Number of subjects: 1603
Study 19772177 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% dextrose in 0.45% NaCl
Number of subjects: 60
Study 19772177 — intervention group
Group type: COMPARATOR
Intervention: Lactated Ringer's solution
Number of subjects: 60
Study 16769915 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery bypass grafting (OPCAB)
Number of subjects: 120
Study 16769915 — intervention group
Group type: COMPARATOR
Intervention: Conventional coronary artery bypass grafting (CCAB)
Number of subjects: 120
Study 15170905 — intervention group
Group type: EXPERIMENTAL
Intervention: Leflunomide in combination with methotrexate (MTX)
Number of subjects: 0
Study 15170905 — intervention group
Group type: EXPERIMENTAL
Intervention: Leflunomide in combination with sulfasalazine
Number of subjects: 0
Study 15170905 — intervention group
Group type: EXPERIMENTAL
Intervention: Leflunomide in combination with infliximab
Number of subjects: 0
Study 15170905 — intervention group
Group type: EXPERIMENTAL
Intervention: Leflunomide in combination with adalimumab
Number of subjects: 0
Study 15170905 — intervention group
Group type: EXPERIMENTAL
Intervention: Lefunomide in combination with etanercept
Number of subjects: 0
Study 15170905 — intervention group
Group type: EXPERIMENTAL
Intervention: Lefunomide in combination with anakinra
Number of subjects: 0
Study 15170905 — intervention group
Group type: COMPARATOR
Intervention: Leflunomide monotherapy
Number of subjects: 0
Study 12575608 — intervention group
Group type: EXPERIMENTAL
Intervention: Astragalus saponin (AS)
Number of subjects: 80
Study 12575608 — intervention group
Group type: COMPARATOR
Intervention: Normal control group
Number of subjects: 80
Study 12575608 — intervention group
Group type: COMPARATOR
Intervention: Burn control group
Number of subjects: 80
Study 9040911 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified obstetrics curriculum at McGill University (MG)
Number of subjects: 57